160 related articles for article (PubMed ID: 8296659)
21. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy.
Lockwood CM
Clin Exp Immunol; 1996 May; 104 Suppl 1():77-82. PubMed ID: 8625549
[TBL] [Abstract][Full Text] [Related]
22. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
23. New aspects in the management of ANCA-positive vasculitis.
Levy J
Nephrol Dial Transplant; 2001 Jul; 16(7):1314-7. PubMed ID: 11427616
[No Abstract] [Full Text] [Related]
24. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
25. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis.
Rossi F; Jayne DR; Lockwood CM; Kazatchkine MD
Clin Exp Immunol; 1991 Feb; 83(2):298-303. PubMed ID: 1993362
[TBL] [Abstract][Full Text] [Related]
26. Animal models of systemic vasculitis.
Mathieson PW; Qasim FJ; Esnault VL; Oliveira DB
J Autoimmun; 1993 Apr; 6(2):251-64. PubMed ID: 8388693
[TBL] [Abstract][Full Text] [Related]
27. [Preliminary results of intravenous immunoglobulins in treating patients with vasculitis].
Antonelli A; Agostini G; Agostini S
Clin Ter; 1992 Sep; 141(9 Pt 2):33-6. PubMed ID: 1468195
[TBL] [Abstract][Full Text] [Related]
28. Part 3: Newer therapies for ANCA-associated vasculitis.
Jayne D
Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S77-9. PubMed ID: 17428377
[No Abstract] [Full Text] [Related]
29. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan.
Muso E; Ito-Ihara T; Ono T; Imai E; Yamagata K; Akamatsu A; Suzuki K
Jpn J Infect Dis; 2004 Oct; 57(5):S17-8. PubMed ID: 15507757
[TBL] [Abstract][Full Text] [Related]
30. Anti-neutrophil cytoplasmic antibody-associated paraneoplastic vasculitis.
Navarro JF; Quereda C; Rivera M; Navarro FJ; Ortuño J
Postgrad Med J; 1994 May; 70(823):373-5. PubMed ID: 8016013
[TBL] [Abstract][Full Text] [Related]
31. [Intravenous immunoglobulin (IVIG)].
Hara M
Nihon Rinsho; 2009 Mar; 67(3):599-605. PubMed ID: 19280939
[TBL] [Abstract][Full Text] [Related]
32. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
Almroth G; Berlin G; Andersson B; Hahn-Zoric M
Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374
[TBL] [Abstract][Full Text] [Related]
33. Prolonged treatment with low-dose intravenous pulse cyclophosphamide may reduce rate of relapse in ANCA-associated vasculitis.
Dhaygude A; Griffith M; Cairns T; McLean A; Palmer A; Taube D
Nephron Clin Pract; 2004; 97(4):c154-9. PubMed ID: 15331939
[TBL] [Abstract][Full Text] [Related]
34. [Role of the titration of anti-neutrophil cytoplasmic antibodies in therapeutic follow-up of patients with systemic vasculitis].
Bergelin A; Subra JF; Carrere F; Chevailler A; Masson C; Szapiro N; Riberi P
Rev Med Interne; 1993; 14(10):1024. PubMed ID: 8009020
[TBL] [Abstract][Full Text] [Related]
35. Serum soluble interleukin 2 receptor levels in anti-neutrophil cytoplasmic autoantibodies--positive systemic vasculitis.
Lai KN; Lockwood CM
Postgrad Med J; 1993 Sep; 69(815):708-11. PubMed ID: 8255836
[TBL] [Abstract][Full Text] [Related]
36. Low predictive value of c-ANCA and anti-alpha-granule antibody for vasculitis in Hong Kong.
Lawton JW; Lee SS
Adv Exp Med Biol; 1993; 336():295-8. PubMed ID: 8296620
[TBL] [Abstract][Full Text] [Related]
37. C-ANCA and p-ANCA positive vasculitis with crescentic glomerulonephritis: the same clinical feature but different immunological pathways?
Grotz W; Röther E; Schollmeyer P
Adv Exp Med Biol; 1993; 336():461-4. PubMed ID: 8296657
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.
Martinez V; Cohen P; Pagnoux C; Vinzio S; Mahr A; Mouthon L; Sailler L; Delaunay C; Sadoun A; Guillevin L;
Arthritis Rheum; 2008 Jan; 58(1):308-17. PubMed ID: 18163506
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
[TBL] [Abstract][Full Text] [Related]
40. Identification of apparent dual ANCA specificities in a subset of patients with systemic vasculitis and crescentic glomerulonephritis.
Teeraratkul P; Thorson JA; Kemp JD; Goeken JA
Adv Exp Med Biol; 1993; 336():455-9. PubMed ID: 8296656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
